SCHEMBL3015650

SCHEMBL3015650

COc1ccc(S(=O)(=O)N2CCN(c3nc(Cc4cccc(C)c4)cs3)CC2)cc1OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.56
TSHR P16473 2/20 0.56
POLB P06746 1/20 0.56
LMNA P02545 4/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
HSD17B10 Q99714 4/20 0.49
USP2 O75604 2/20 0.49
GLA P06280 1/20 0.49
MAPK1 P28482 1/20 0.49
KDM4E B2RXH2 2/20 0.48
ALDH1A1 P00352 1/20 0.48
HSD11B1 P28845 1/20 0.48
GPBAR1 Q8TDU6 1/20 0.47
HDAC3 O15379 2/20 0.47
HDAC4 P56524 2/20 0.47
HDAC1 Q13547 2/20 0.47
HDAC7 Q8WUI4 2/20 0.47
HDAC2 Q92769 2/20 0.47
HDAC10 Q969S8 2/20 0.47
HDAC11 Q96DB2 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017131 0.92 HTT (0.53) HTTTSHRPOLBLMNASMN1; SMN2
SCHEMBL3010379 0.91 HSD17B10 (0.54) HTTTSHRPOLBLMNASMN1; SMN2
SCHEMBL3015174 0.91 HSD17B10 (0.55) HTTTSHRPOLBLMNASMN1; SMN2
SCHEMBL3013884 0.91 TSHR (0.53) HTTTSHRPOLBLMNASMN1; SMN2
SCHEMBL3003581 0.90 TSHR (0.52) HTTTSHRPOLBLMNASMN1; SMN2
SCHEMBL3012247 0.90 LMNA (0.54) HTTTSHRPOLBLMNASMN1; SMN2
SCHEMBL3019183 0.89 MAPT (0.54) HTTTSHRPOLBLMNASMN1; SMN2
SCHEMBL3017911 0.88 HTT (0.54) HTTTSHRPOLBLMNASMN1; SMN2
SCHEMBL3011233 0.88 ALDH1A1 (0.49) HTTTSHRPOLBLMNASMN1; SMN2
SCHEMBL3009926 0.88 MAPT (0.46) TSHRLMNASMN1; SMN2HSD17B10USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA HTT 2/4885TSHR 3320/4885POLB 4649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.